Fluorouracil News and Research

RSS

Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.

Novel 3D-printed esophageal stents could revolutionize the delivery of cancer treatment

World-first 3D printed esophageal stents developed by the University of South Australia could revolutionize the delivery of chemotherapy drugs to provide more accurate, effective and personalized treatment for patients with esophageal cancer.

3 Feb 2021

Machine learning increases the accuracy of anti-cancer drug response predictions

With the advent of pharmacogenomics, machine learning research is well underway to predict the patients' drug response that varies by individual from the algorithms derived from previously collected data on drug responses.

2 Nov 2020

COMBAT study shows how pancreatic cancer patients can benefit from immunotherapy

Working with an international team of researchers, HonorHealth Research Institute and the Translational Genomics Research Institute, an affiliate of City of Hope, were instrumental in one of the first clinical trials showing how pancreatic cancer patients can benefit from immunotherapy, according to a four-year study published in a premier scientific journal, Nature Medicine.

11 Aug 2020

First clinical trial could become an effective way to deliver chemotherapy to abdominal cancer patients

City of Hope surgical researchers are the first in the nation to open a clinical trial that could one day become an effective way to deliver chemotherapy to abdominal cancer patients who currently have very few treatment options.

11 Aug 2020

Stanford researchers develop a portable device for rapidly detecting blood ammonia levels

Seated around the dinner table, faculty affiliated with Stanford ChEM-H - one of Stanford University's interdisciplinary institutes - spoke one-by-one, pitching ideas for collaborative research.

21 Jul 2020

Researchers develop bioprinted skin model of cutaneous squamous cell carcinoma

The cover for issue 27 of Oncotarget features "Bimodal imaging examples of control and treated tumors (red) before and after the treatment period," by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.

7 Jul 2020

Study finds carboplatin-paclitaxel as the optimal chemotherapy for anal cancer

Up to now, patients with inoperable anal cancer, a rare disease, have not had a standard-of-care treatment; palliative care has been the routine for them.

19 Jun 2020

3D printing technology can inhibit the proliferation of cancer cells in vitro

Doctors could soon be administering an entire course of treatment for life-threatening conditions with a 3D printed capsule controlled by magnetic fields thanks to advances made by the University of Sussex researchers.

10 Jun 2020

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.

19 May 2020

MU researcher finds four antiviral drugs effective in inhibiting novel coronavirus

Now, a researcher at the University of Missouri has found that four antiviral drugs, including remdesivir, a drug originally developed to treat Ebola, are effective in inhibiting the replication of the coronavirus causing COVID-19.

4 May 2020

Cream infused with microscopic STAR particles could facilitate better treatment of skin diseases

Skin diseases affect half of the world's population, but many treatments are not effective, require frequent injections, or cause significant side effects.

10 Mar 2020

New type of adoptive cell therapy could target prostate and pancreatic cancers in humans

In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

5 Mar 2020

Researchers identify new pathway as biological target for colon cancer

Researchers have found a way to help make chemotherapy more effective in treating colon cancer. They identified a new pathway (RICTOR/mTORC2) as a biological target for the disease.

13 Jan 2020

Study: Checkpoint inhibitor prolongs survival in patients with head and neck cancers

The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC). The data was published today in the journal The Lancet.

1 Nov 2019

Study: High levels of circ E7 is a positive prognostic marker in anal squamous cell carcinoma

High levels of circ E7 by quantitative RT-PCR predicted improved overall survival in ASCC and analysis of The Cancer Genome Atlas sequencing from HPV-positive head and neck cancer and cervical cancer suggested high circ E7 marked improved survival in 875 subjects.

17 Oct 2019

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

Results presented today at the ESMO Congress 2019, Barcelona 27 September - 01 October, during the second Proffered Paper Session on Gastrointestinal tumors (colorectal) by VHIO's Director, Josep Tabernero, show that the triplet combination of the BRAF inhibitor, encorafenib, MEK inhibitor, binimetinib, and EGFR inhibitor, cetuximab, not only significantly improves overall survival but also increases objective response rates compared with standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer.

30 Sep 2019

Microrna-based therapy may prove to be effective against chemotherapy-resistant cancers

A technology that manipulates microRNAs developed by Jingfang Ju, PhD, a biochemist and Professor in the Department of Pathology at the Renaissance School of Medicine at Stony Brook University, and colleagues has shown promise when used as anti-cancer therapeutic.

19 Sep 2019